Literature DB >> 27463325

Pharmacophores in Drug Research.

Thierry Langer1.   

Abstract

The pharmacophore concept in modern drug research is highlighted and the most important use examples and success stories are reviewed. These include papers from method development as well as from application areas. As indicated by the number of publications available, the pharmacophore approach has proven to be extremely useful as interface between medicinal and computational chemistry, both in virtual screening and library design for efficient hit discovery, but also in the optimization of lead compounds to clinical candidates. Recent studies focus on the usage of parallel screening using pharmacophore models for bio-activity profiling and early stage risk assessment of potential side effects and toxicity due to interaction of drug candidates with anti-targets.
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Affinity fingerprint; Database mining; Drug design; Ligand profiling; Pharmacophore; Virtual screening

Year:  2010        PMID: 27463325     DOI: 10.1002/minf.201000022

Source DB:  PubMed          Journal:  Mol Inform        ISSN: 1868-1743            Impact factor:   3.353


  3 in total

1.  Emerging topics in structure-based virtual screening.

Authors:  Giulio Rastelli
Journal:  Pharm Res       Date:  2013-03-07       Impact factor: 4.200

2.  Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening.

Authors:  Sayalee R Chavan; Radha Charan Dash; M Sarwar Alam; Raj R Hirwani
Journal:  Mol Divers       Date:  2014-08-12       Impact factor: 2.943

3.  In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.

Authors:  Abdul Wadood; Mehreen Ghufran; Syed Fahad Hassan; Huma Khan; Syed Sikandar Azam; Umer Rashid
Journal:  Pharm Biol       Date:  2016-09-21       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.